Insights on Novel Technology in Pain Management With Abuse-Deterrent Extended-Release Opioids

Sponsored by Collegium Pharmaceutical, Inc.

This activity is not certified for credit.

Friday, September 8

Start Time

End Time

Castellana Ballroom
Level 3

Program Description
This program will discuss key issues around opioid abuse, misuse, and diversion. An overview of opioid formulations with abuse-deterrent properties will be provided before featuring a description of the DETERx® microsphere delivery system and summarizing the Xtampza® ER (oxycodone) clinical profile. Xtampza® ER is Collegium's first product utilizing the DETERx® technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

DETERx is a registered trademark of Collegium Pharmaceutical, Inc.

Gerard DeGregoris, III, MD

Pre-registration not required. Please arrive at least 15 minutes prior to start time.

Contact Name
Sheri Selvey, PharmD

Contact Phone
(317) 615-9891

Contact email


Related Content